US EditionPublished • loading... • Updated
Celltrion enters Japanese market for arthritis treatments with new biosimilar
Summary by The Korea Times
2 Articles
2 Articles
Celltrion Launches Autoimmune Disease Treatment Aptozma in Japan; Biosimilar of Actemra Developed by Switzerland's Roche; Expands Autoimmune Disease Product Lineup in Japanese Market to a Total of Four. Celltrion announced on the 28th that the autoimmune disease treatment Aptozma (active ingredient: tocilizumab) has been launched in Japan. Aptozma is a biosimilar of Actemra developed by Switzerland's Roche...
Coverage Details
Total News Sources2
Leaning Left1Leaning Right1Center0Last UpdatedBias Distribution50% Left, 50% Right
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
50% Right
L 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
